Article Text

Download PDFPDF

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD
  1. James L Kreindler1,
  2. Michael L Watkins2,
  3. Sally Lettis3,
  4. Ruth Tal-Singer1 and
  5. Nicholas Locantore1
  1. 1GSK R&D, King of Prussia, Pennsylvania, USA
  2. 2GSK R&D, Research Triangle Park, North Carolina, USA
  3. 3GSK R&D, Uxbridge, UK
  1. Correspondence to Dr James L Kreindler; james.l.kreindler{at}gsk.com

Abstract

Introduction Sputum and blood eosinophil counts have attracted attention as potential biomarkers in chronic obstructive pulmonary disease (COPD). One question regarding the use of blood eosinophils as a biomarker in COPD is whether their levels are affected by the use of inhaled corticosteroids (ICS), which are commonly prescribed for COPD.

Methods We performed a retrospective analysis of peripheral blood leucocytes from a previously completed clinical trial that examined effects of ICS in steroid-naïve patients with COPD.

Results and conclusion The data show that the ICS-containing treatment arms (containing fluticasone propionate) had a small effect on peripheral blood eosinophils in steroid-naïve patients with COPD.

Trial registration number NCT00358358; Post-results.

  • Eosinophil Biology
  • COPD Pharmacology

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.